Genmab A/S (GMAB) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Genmab A/s.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.577 Hello and welcome to the GenMAP full year 2025 financial results conference call. 00:00:05.577 -- 00:00:08.099 As a reminder, this conference call is being recorded. 00:00:08.099 -- 00:00:12.924 During this telephone conference, you may be presented with forward-looking statements 00:00:12.924 -- 00:00:18.110 that include words such as beliefs, anticipates, plans, or expects. 00:00:18.110 -- 00:00:22.294 Actual results may differ materially, for example, as a result of delayed or unsuccessful 00:00:22.294 -- 00:00:27.679 development projects. GenMAP is not under any obligation to update statements regarding 00:00:27.679 -- 00:00:32.440 the future nor to confirm such statements in relation to actual results, unless this 00:00:32.440 -- 00:00:35.023 is required by law. 00:00:35.023 -- 00:00:40.129 Please also note, GERMAP may hold your personal data as indicated by you as 00:00:40.129 -- 00:00:45.475 a part of our investor relations outreach activities in order to update you on GERMAP 00:00:45.475 -- 00:00:47.738 going forward. 00:00:47.738 -- 00:00:52.383 Please refer to our website for more information on GERMAP and our privacy policy. 00:00:52.383 -- 00:00:57.049 I would now like to hand the conference over to our first speaker today, Jan van der 00:00:57.049 -- 00:00:59.853 Winkel. Please go ahead. 00:00:59.853 -- 00:01:02.698 Hello and welcome to our financial results call for 2025. 00:01:02.698 -- 00:01:07.846 With me today is our Chief Financial Officer, Anthony Pagano, and 00:01:07.846 -- 00:01:10.490 our Chief Commercial Officer, Brad Bailey. 00:01:10.490 -- 00:01:14.957 For the Q&A, we will be joined by our Chief Medical Officer, Tanya Mahdi, and our Chief 00:01:14.957 -- 00:01:18.179 Development Officer, Judith Klimovski. ...